Last updated 2026-06-18
- Raised $3M funding round, Jan 2019
Total raised
$3.0M
Last: 2019-01
Stage
Seed
Founded
2017
Headcount
3
HQ
, Israel
Sector
Health Tech & Life Sciences
About
Moya Bio is developing a novel class of tumor immune conditioning agents. The company's inhibitors of the FAT10 pathway are designed to increase the impact of immunotherapy by sensitizing the tumor to immune-mediated cytotoxicity, to benefit additional patient populations. Moya Bio's translational data demonstrates a correlation between FAT10 down regulation, increased T-cell infiltration into the tumor microenvironment, and inhibition of tumor growth. The molecular mechanism underlying Moya's FAT10 inhibition platform supports a synergistic effect with immune checkpoint inhibitors, which is expected to enhance their clinical efficacy.
Funding history · 1 round · $3.0M total
2019-01
Q&A
- What is Moya Bio's primary focus?
- Moya Bio is developing a novel class of tumor immune conditioning agents, specifically inhibitors of the FAT10 pathway, to enhance the impact of immunotherapy.
- When was Moya Bio founded?
- Moya Bio was founded in December 2017.
- What is the current status of Moya Bio?
- Moya Bio is currently inactive, having ceased operations in November 2024.
- How much funding has Moya Bio raised in total?
- Moya Bio has raised a total of $3,000,000.
- Which investors participated in Moya Bio's funding round?
- In January 2019, Moya Bio secured funding from FutuRx and RMGP Biopharma Investment Fund.
- What is Moya Bio's employee count?
- Moya Bio has an employee count in the 1-10 range.
- What is the primary sector of Moya Bio?
- Moya Bio operates within the Health Tech & Life Sciences sector.
Team · 1
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
medical-technologiesimmunotherapyhospitalsbiotechnologycancerlife-sciences
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2017-12 |
|---|---|
| Employees (exact) | 3 |
| Status reason | Non Active, Nov 2024 ceased to operate |